経口抗生物質の世界市場2020–2027:クラス別(ベータラクタムおよびベータラクタマーゼ阻害剤、キノロン、マクロライド、その他)、用途別、薬剤成分別、活動スペクトル別、薬物種類別

◆英語タイトル:Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 2020–2027
◆商品コード:AMR20PL061
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年6月
◆ページ数:329
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,599 ⇒換算¥692,895見積依頼/購入/質問フォーム
5 UserUSD7,447 ⇒換算¥781,935見積依頼/購入/質問フォーム
Enterprise UserUSD10,385 ⇒換算¥1,090,425見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、経口抗生物質の世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、クラス別(ベータラクタム・ベータラクタマーゼ阻害剤、キノロン、マクロライド、その他)分析、用途別分析、薬剤成分別分析、活動スペクトル別分析、薬物種類別分析、地域別分析、企業情報など、今後の市場展望をまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・経口抗生物質の世界市場規模:クラス別(ベータラクタム・ベータラクタマーゼ阻害剤、キノロン、マクロライド、その他)
・経口抗生物質の世界市場規模:用途別
・経口抗生物質の世界市場規模:薬剤成分別
・経口抗生物質の世界市場規模:活動スペクトル別
・経口抗生物質の世界市場規模:薬物種類別
・経口抗生物質の世界市場規模:地域別
・企業情報
【レポートの概要】

The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.

Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most of countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.

There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global oral antibiotics market is segmented on the basis of class, application drug origin, spectrum of activity, application, and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Depending on class, the market is categorized into Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others. The beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018. The segment is a major revenue contributor, owing to its broad-spectrum of activity A broad-spectrum antibiotic fights both Gram-negative and Gram-positive bacteria as well as effective on the multiple groups of bacterial infections.

On the basis of application, the oral antibiotics market is classified into community-acquired respiratory tract infections (CARTIs), urinary tract infections (UTIs), dental, and others. The CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies.
On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic, and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.

KEY MARKET SEGMENTS
By Class
• Beta Lactam and Beta Lactamase Inhibitors
o Penicillin
 Broad Spectrum Penicillin
 Mid/Narrow Spectrum Penicillin
o Cephalosporin
o Others
• Quinolone
• Macrolide
• Others

By Application
• Community-respiratory tract infections (CARTIS)
o Upper Respiratory Tract Infections (URTI)
o Lower Respiratory Tract Infections (LRTI)
• Urinary acquired tract infections (UTIS)
• Dental
o Combination
o Monotherapies
• Others

By Drug Origin
• Natural
• Semisynthetic
• Synthetic

By Spectrum of Activity
• Broad-spectrum Antibiotic
• Narrow-spectrum Antibiotic

By Drug Type
• Branded
• Generic

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o Spain
o Italy
o UK
o Russia
o Rest of Europe
• Asia-Pacific
o Japan
o India
o China
o Pakistan
o Vietnam
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Turkey
o Rest of LAMEA

List of key players profiled in the report
• Abbott Laboratories
• Allergan Plc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Mylan N.V.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Market share analysis, 2018
3.4.Porter’s five forces analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in consumption in low-and middle-income countries (LMICs)
3.5.1.2.Rise in prevalence of infectious diseases
3.5.1.3.Development of novel approaches

3.5.2.Restraints

3.5.2.1.Development of antibiotic resistance
3.5.2.2.Time consuming approvals

3.5.3.Opportunities

3.5.3.1.Discovery of advanced therapies to treat antibiotic-resistance.

3.6.Impact analysis of COVID-19 on oral antibiotics market

CHAPTER 4:ORAL ANTIBIOTICS MARKET, BY CLASS

4.1.Overview

4.1.1.Market size and forecast, by class

4.2.Beta lactam and beta lactamase inhibitors

4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Penicillin

4.2.2.1.1.Market size and forecast, by type

4.2.2.1.1.1.Broad-spectrum penicillin
4.2.2.1.1.2.Mid/Narrow-spectrum penicillin

4.2.2.2.Cephalosporin

4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by molecule

4.2.2.3.Others

4.2.2.3.1.Market size and forecast

4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country

4.3.Quinolones

4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Macrolides

4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Others

4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:ORAL ANTIBIOTICS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Community-acquired respiratory tract infections (CARTIs)

5.2.1.Market size and forecast, by type

5.2.1.1.Upper Respiratory Tract Infections (URTI)

5.2.1.1.1.Market size and forecast
5.2.1.1.2.Market size and forecast, by molecule

5.2.1.2.Lower Respiratory Tract Infections (LRTIs)

5.2.1.2.1.Market size and forecast
5.2.1.2.2.Market size and forecast, by molecule

5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Urinary tract infections (UTIs)

5.3.1.Market size and forecast, by molecule
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Dental

5.4.1.Market size and forecast, by type

5.4.1.1.Combination

5.4.1.1.1.Market size and forecast
5.4.1.1.2.Market size and forecast, by molecule

5.4.1.2.Monotherapies

5.4.1.2.1.Market size and forecast
5.4.1.2.2.Market size and forecast, by molecule

5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN

6.1.Overview

6.1.1.Market size and forecast

6.2.Natural

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Semisynthetic

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Synthetic

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

7.1.Overview

7.1.1.Market size and forecast

7.2.Broad-spectrum antibiotic

7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country

7.3.Mid/Narrow-spectrum antibiotic

7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country

CHAPTER 8:ORAL ANTIBIOTICS MARKET, BY DRUG TYPE

8.1.Overview

8.1.1.Market size and forecast

8.2.Branded

8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country

8.3.Generics

8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country

CHAPTER 9:ORAL ANTIBIOTICS MARKET, BY REGION

9.1.Overview

9.1.1.Market size and forecast

9.2.North America

9.2.1.Key market trends and opportunities
9.2.2.North America antibiotics market, by country

9.2.2.1.U.S. oral antibiotics market, by class
9.2.2.2.U.S. oral antibiotics market, by application
9.2.2.3.U.S. oral antibiotics market, by drug origin
9.2.2.4.U.S. oral antibiotics market, by spectrum of activity
9.2.2.5.U.S. oral antibiotics market, by Drug type
9.2.2.6.Canada oral antibiotics market, by class
9.2.2.7.Canada oral antibiotics market, by application
9.2.2.8.Canada oral antibiotics market, by drug origin
9.2.2.9.Canada oral antibiotics market, by spectrum of activity
9.2.2.10.Canada oral antibiotics market, by drug type
9.2.2.11.Mexico oral antibiotics market, by class162
9.2.2.12.Mexico oral antibiotics market, by application
9.2.2.13.Mexico oral antibiotics market, by drug origin
9.2.2.14.Mexico oral antibiotics market, by spectrum of activity
9.2.2.15.Mexico oral antibiotics market, by drug type

9.2.3.North America oral antibiotics market, by class
9.2.4.North America oral antibiotics market, by application
9.2.5.North America oral antibiotics market, by drug origin
9.2.6.North America oral antibiotics market, by spectrum of activity
9.2.7.North America antibiotics market, by drug type

9.3.Europe

9.3.1.Key market trends and opportunities
9.3.2.Europe oral antibiotics market, by country

9.3.2.1.Germany oral antibiotics market, by class
9.3.2.2.Germany oral antibiotics market, by application
9.3.2.3.Germany oral antibiotics market, by drug origin
9.3.2.4.Germany oral antibiotics market, by spectrum of activity
9.3.2.5.Germany oral antibiotics market, by Drug type
9.3.2.6.France oral antibiotics market, by class
9.3.2.7.France oral antibiotics market, by application
9.3.2.8.France oral antibiotics market, by drug origin
9.3.2.9.France oral antibiotics market, by spectrum of activity
9.3.2.10.France oral antibiotics market, by drug type
9.3.2.11.Spain oral antibiotics market, by class181
9.3.2.12.Spain oral antibiotics market, by application
9.3.2.13.Spain oral antibiotics market, by drug origin
9.3.2.14.Spain oral antibiotics market, by spectrum of activity
9.3.2.15.Spain oral antibiotics market, by drug type
9.3.2.16.Italy oral antibiotics market, by class185
9.3.2.17.Italy oral antibiotics market, by application
9.3.2.18.Italy oral antibiotics market, by drug origin
9.3.2.19.Italy oral antibiotics market, by spectrum of activity
9.3.2.20.Italy oral antibiotics market, by drug type
9.3.2.21.UK oral antibiotics market, by class
9.3.2.22.UK oral antibiotics market, by application
9.3.2.23.UK oral antibiotics market, by drug origin
9.3.2.24.UK oral antibiotics market, by spectrum of activity
9.3.2.25.UK oral antibiotics market, by drug type
9.3.2.26.Russia oral antibiotics market, by class
9.3.2.27.Russia oral antibiotics market, by application
9.3.2.28.Russia oral antibiotics market, by drug origin
9.3.2.29.Russia oral antibiotics market, by spectrum of activity
9.3.2.30.Russia oral antibiotics market, by drug type
9.3.2.31.Rest of Europe oral antibiotics market, by class
9.3.2.32.Rest of Europe oral antibiotics market, by application
9.3.2.33.Rest of Europe oral antibiotics market, by drug origin
9.3.2.34.Rest of Europe oral antibiotics market, by spectrum of activity
9.3.2.35.Rest of Europe oral antibiotics market, by drug type

9.3.3.Europe oral antibiotics market, by class
9.3.4.Europe oral antibiotics market, by application
9.3.5.Europe oral antibiotics market, by drug origin
9.3.6.Europe oral antibiotics market, by spectrum of activity
9.3.7.Europe oral antibiotics market, by drug type

9.4.Asia-Pacific

9.4.1.Key market trends and opportunities
9.4.2.Asia-Pacific oral antibiotics market, by country

9.4.2.1.Japan oral antibiotics market, by class
9.4.2.2.Japan oral antibiotics market, by application
9.4.2.3.Japan oral antibiotics market, by drug origin
9.4.2.4.Japan oral antibiotics market, by spectrum of activity
9.4.2.5.Japan oral antibiotics market, by drug type
9.4.2.6.India oral antibiotics market, by class
9.4.2.7.India oral antibiotics market, by application
9.4.2.8.India oral antibiotics market, by drug origin
9.4.2.9.India oral antibiotics market, by spectrum of activity
9.4.2.10.India oral antibiotics market, by drug type
9.4.2.11.China oral antibiotics market, by class
9.4.2.12.China oral antibiotics market, by application
9.4.2.13.China oral antibiotics market, by drug origin
9.4.2.14.China oral antibiotics market, by spectrum of activity
9.4.2.15.China oral antibiotics market, by drug type
9.4.2.16.Pakistan oral antibiotics market, by class
9.4.2.17.Pakistan oral antibiotics market, by application
9.4.2.18.Pakistan oral antibiotics market, by drug origin
9.4.2.19.Pakistan oral antibiotics market, by spectrum of activity
9.4.2.20.Pakistan oral antibiotics market, by Drug type
9.4.2.21.Vietnam oral antibiotics market, by class
9.4.2.22.Vietnam oral antibiotics market, by application
9.4.2.23.Vietnam oral antibiotics market, by drug origin
9.4.2.24.Vietnam oral antibiotics market, by spectrum of activity
9.4.2.25.Vietnam oral antibiotics market, by Drug type
9.4.2.26.Rest of Asia-Pacific oral antibiotics market, by class
9.4.2.27.Rest of Asia-Pacific oral antibiotics market, by application
9.4.2.28.Rest of Asia-Pacific oral antibiotics market, by drug origin
9.4.2.29.Rest of Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.2.30.Rest of Asia-Pacific oral antibiotics market, by drug type

9.4.3.Asia-Pacific oral antibiotics market, by class
9.4.4.Asia-Pacific oral antibiotics market, by application
9.4.5.Asia-Pacific oral antibiotics market, by drug origin
9.4.6.Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.7.Asia-Pacific oral antibiotics market, by drug type

9.5.LAMEA

9.5.1.Key market trends and opportunities
9.5.2.LAMEA antibiotics market, by country

9.5.2.1.Brazil oral antibiotics market, by class
9.5.2.2.Brazil oral antibiotics market, by application
9.5.2.3.Brazil oral antibiotics market, by drug origin
9.5.2.4.Brazil oral antibiotics market, by spectrum of activity
9.5.2.5.Brazil oral antibiotics market, by drug type
9.5.2.6.Saudi Arabia oral antibiotics market, by class
9.5.2.7.Saudi Arabia oral antibiotics market, by application
9.5.2.8.Saudi Arabia oral antibiotics market, by drug origin
9.5.2.9.Saudi Arabia oral antibiotics market, by spectrum of activity
9.5.2.10.Saudi Arabia oral antibiotics market, by application
9.5.2.11.South Africa oral antibiotics market, by class
9.5.2.12.South Africa oral antibiotics market, by application
9.5.2.13.South Africa oral antibiotics market, by drug origin
9.5.2.14.South Africa oral antibiotics market, by spectrum of activity
9.5.2.15.South Africa oral antibiotics market, by drug type
9.5.2.16.Turkey oral antibiotics market, by class
9.5.2.17.Turkey oral antibiotics market, by application
9.5.2.18.Turkey oral antibiotics market, by drug origin
9.5.2.19.Turkey oral antibiotics market, by spectrum of activity
9.5.2.20.Turkey oral antibiotics market, by drug type
9.5.2.21.Rest of LAMEA oral antibiotics market, by class
9.5.2.22.Rest of LAMEA oral antibiotics market, by application
9.5.2.23.Rest of LAMEA oral antibiotics market, by drug origin
9.5.2.24.Rest of LAMEA oral antibiotics market, by spectrum of activity
9.5.2.25.Rest of LAMEA oral antibiotics market, by drug type

9.5.3.LAMEA antibiotics market, by class
9.5.4.LAMEA antibiotics market, by application
9.5.5.LAMEA antibiotics market, by drug origin
9.5.6.LAMEA antibiotics market, by spectrum of activity
9.5.7.LAMEA antibiotics market, by drug type

CHAPTER 10:COMPANY PROFILES

10.1.ABBOTT LABORATORIES

10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance

10.2.ALLERGAN PLC

10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments

10.3.F. HOFFMANN-LA ROCHE LTD.

10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance
10.3.6.Key strategic moves and developments

10.4.GLAXOSMITHKLINE PLC

10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.4.6.Key strategic moves and developments

10.5.MERCK & CO., INC.

10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Business performance
10.5.6.Key strategic moves and developments

10.6.MYLAN N.V.

10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments

10.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)

10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Operating business segments
10.7.4.Product portfolio
10.7.5.Business performance
10.7.6.Key strategic moves and developments

10.8.PFIZER INC.

10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Operating Product
10.8.5.Business performance
10.8.6.Key strategic moves and developments

10.9.SANOFI

10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.9.6.Key strategic moves and developments

10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL ORAL ANTIBIOTICS MARKET, BY CLASS, 2018–2027 ($MILLION)
TABLE 02.BETA LACTAM & BETA LACTAMASE INHIBITORS ANTIBIOTICS MARKET, BY TYPE, 2018–2027 ($MILLION)
TABLE 03.PENICILLIN ORAL ANTIBIOTICS MARKET, BY TYPE, 2018–2027 ($MILLION)
TABLE 04.ORAL ANTIBIOTICS MARKET FOR CEPHALOSPORIN, BY MOLECULE, 2018–2027 ($MILLION)
TABLE 05.ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY REGION, 2018–2027 ($MILLION)
TABLE 06.ANTIBIOTICS MARKET FOR QUINOLONES, BY REGION, 2018–2027 ($MILLION)
TABLE 07.ANTIBIOTICS MARKET FOR MACROLIDES, BY REGION, 2018–2027 ($MILLION)
TABLE 08.ANTIBIOTICS MARKET FOR OTHER CLASSES BY REGION, 2018–2027 ($MILLION)
TABLE 09.GLOBAL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018–2027 ($MILLION)
TABLE 10.ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY TYPE, 2018–2027 ($MILLION)
TABLE 11.ORAL ANTIBIOTICS MARKET FOR UPPER RESPIRATORY TRACT INFECTIONS, BY MOLECULE, 2018–2027 ($MILLION)
TABLE 12.ORAL ANTIBIOTICS MARKET FOR LOWER RESPIRATORY TRACT INFECTIONS, BY MOLECULE, 2018–2027 ($MILLION)
TABLE 13.ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY REGION, 2018–2027 ($MILLION)
TABLE 14.ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY MOLECULE, 2018–2027 ($MILLION)
TABLE 15.ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY REGION, 2018–2027 ($MILLION)
TABLE 16.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY TYPE, 2018–2027 ($MILLION)
TABLE 17.ORAL ANTIBIOTICS MARKET FOR DENTAL COMBINATION ORAL ANTIBIOTICS, BY MOLECULE, 2018–2027 ($MILLION)
TABLE 18.ORAL ANTIBIOTICS MARKET FOR DENTAL MONOTHERAPIES, BY MOLECULE, 2018–2027 ($MILLION)
TABLE 19.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY REGION, 2018–2027 ($MILLION)
TABLE 20.ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2018–2027 ($MILLION)
TABLE 21.GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018–2027 ($MILLION)
TABLE 22.ORAL ANTIBIOTICS MARKET FOR NATURAL, BY REGION, 2018–2027 ($MILLION)
TABLE 23.ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY REGION, 2018–2027 ($MILLION)
TABLE 24.ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY REGION, 2018–2027 ($MILLION)
TABLE 25.GLOBAL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018–2027 ($MILLION)
TABLE 26.ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ORAL ANTIBIOTIC, BY REGION, 2018–2027 ($MILLION)
TABLE 27.ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ORAL ANTIBIOTIC, BY REGION, 2018–2027 ($MILLION)
TABLE 28.GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018–2027 ($MILLION)
TABLE 29.BRANDED ANTIBIOTICS MARKET, BY REGION, 2018–2027 ($MILLION)TABLE 30.GENERIC ANTIBIOTICS MARKET, BY REGION, 2018–2027 ($MILLION)
TABLE 31.ORAL ANTIBIOTICS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 32.NORTH AMERICA ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
TABLE 33.U.S. ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 34.U.S. ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 35.U.S. ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 36.U.S. ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 37.U.S. ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 38.CANADA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 39.CANADA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 40.CANADA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 41.CANADA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 42.CANADA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 43.MEXICO ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 44.MEXICO ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 45.MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 46.MEXICO ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 47.MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 48.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 49.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 50.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 51.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 52.NORTH AMERICA ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 53.EUROPE ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
TABLE 54.GERMANY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 55.GERMANY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 56.GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 57.GERMANY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 58.GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 59.FRANCE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 60.FRANCE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 61.FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 62.FRANCE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 63.FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 64.SPAIN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 65.SPAIN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 66.SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 67.SPAIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 68.SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 69.ITALY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 70.ITALY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 71.ITALY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 72.ITALY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 73.ITALY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 74.UK ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 75.UK ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 76.UK ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 77.UK ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 78.UK ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 79.RUSSIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 80.RUSSIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 81.RUSSIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 82.RUSSIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 83.RUSSIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 84.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 85.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 86.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 87.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 88.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 89.EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 90.EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 91.EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 92.EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 93.EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 94.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
TABLE 95.JAPAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 96.JAPAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 97.JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 98.JAPAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 99.JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 100.INDIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 101.INDIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 102.INDIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 103.INDIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 104.INDIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 105.CHINA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 106.CHINA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 107.CHINA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 108.CHINA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 109.CHINA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 110.PAKISTAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 111.PAKISTAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 112.PAKISTAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 113.PAKISTAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 114.PAKISTAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 115.VIETNAM ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 116.VIETNAM ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 117.VIETNAM ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 118.VIETNAM ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 119.VIETNAM ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 120.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 121.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 122.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 123.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 124.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 125.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 126.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 127.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 128.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 129.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 130.LAMEA ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
TABLE 131.BRAZIL ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 132.BRAZIL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 133.BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 134.BRAZIL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 135.BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 136.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 137.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 138.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 139.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 140.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 141.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 142.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 143.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 144.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 145.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 146.TURKEY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 147.TURKEY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 148.TURKEY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 149.TURKEY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 150.TURKEY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 151.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 152.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 153.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 154.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 155.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 156.LAMEA ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 157.LAMEA ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 158.LAMEA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
TABLE 159.LAMEA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
TABLE 160.LAMEA ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 161.ABBOTT: COMPANY SNAPSHOT
TABLE 162.ABBOTT: OERATING SEGMENT
TABLE 163.ABBOTT: PRODUCT PORTFOLIO
TABLE 164.ALLERGAN: COMPANY SNAPSHOT
TABLE 165.ALLERGAN: OPERATING SEGMENTS
TABLE 166.ALLERGAN: PRODUCT PORTFOLIO
TABLE 167.ROCHE: COMPANY SNAPSHOT
TABLE 168.ROCHE: OERATING SEGMENT
TABLE 169.ROCHE: PRODUCT PORTFOLIO
TABLE 170.GSK: COMPANY SNAPSHOT
TABLE 171.GSK: OPERATING SEGMENTS
TABLE 172.GSK: PRODUCT PORTFOLIO
TABLE 173.MERCK: COMPANY SNAPSHOT
TABLE 174.MERCK: OPERATING SEGMENTS
TABLE 175.MERCK PRODUCT PORTFOLIO
TABLE 176.MYLAN: COMPANY SNAPSHOT
TABLE 177.MYLAN: OPERATING SEGMENTS
TABLE 178.ALLERGAN: PRODUCT PORTFOLIO
TABLE 179.NOVARTIS: COMPANY SNAPSHOT
TABLE 180.NOVARTIS: OPERATING SEGMENTS
TABLE 181.NOVARTIS: PRODUCT PORTFOLIO
TABLE 182.PFIZER: COMPANY SNAPSHOT
TABLE 183.PFIZER: OPERATING SEGMENTS
TABLE 184.PFIZER: PRODUCT PORTFOLIO
TABLE 185.SANOFI: COMPANY SNAPSHOT
TABLE 186.SANOFI: OPERATING SEGMENTS
TABLE 187.SANOFI: PRODUCT PORTFOLIO
TABLE 188.TEVA: COMPANY SNAPSHOT
TABLE 189.TEVA: OPERATING SEGMENTS
TABLE 190.TEVA: PRODUCT PORTFOLIO

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[経口抗生物質の世界市場2020–2027:クラス別(ベータラクタムおよびベータラクタマーゼ阻害剤、キノロン、マクロライド、その他)、用途別、薬剤成分別、活動スペクトル別、薬物種類別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆